World Pharma News Digest - 05.10.2009

0 views
Skip to first unread message

Ruslan David

unread,
Oct 5, 2009, 3:41:01 AM10/5/09
to worldph...@googlegroups.com
Takeda to Establish Four Sales and Marketing Subsidiaries 
Takeda Pharmaceutical Company Limited (Osaka, Japan, "Takeda") will establish four new commercial subsidiaries covering Mexico, Turkey, Sweden, Norway, Denmark, Belgium and Luxembourg. The new subsidiaries - Takeda Pharmaceuticals Mexico, S.A. de C.V., Takeda Pharmaceuticals Trade, LLP (Turkey), Takeda Pharmaceuticals Nordics AB (Sweden), and Takeda Pharmaceuticals Benelux SPRL (Belgium) - are part of Takeda's strategic global expansion efforts. 
Read more... 
http://www.worldpharmanews.com/content/view/960/1/
 
Novartis oral MS therapy FTY720 significantly reduces relapses and disability progression 
Initial results from the two-year Phase III FREEDOMS study show that oral FTY720 (fingolimod) was significantly superior to placebo in reducing both relapses and disability progression in patients with relapsing-remitting multiple sclerosis (MS)[1] - one of the leading causes of neurological disability in young adults[3]. 
Read more... 
http://www.worldpharmanews.com/content/view/959/1/
 
102.3 Million Patients Online for Prescription Drug Information, Doubled in Past Four Years 
Since 2005, the number of patients using the Internet to research prescription drug information has doubled to 102.3 million. Similarly, the overall number of eHealth Consumers, those online for any health and medical information, has also grown significantly over the past four years. This market now stands at 157.5 million consumers, or 1.6 times the number of eHealth Consumers in 2005. 
Read more... 
http://www.worldpharmanews.com/content/view/958/1/
 
Merck Submits Application for Cladribine Tablets 
Merck KGaA announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Cladribine Tablets, Merck's proprietary investigational oral formulation of cladribine, as a therapy for reducing relapses in people with relapsing forms of multiple sclerosis (MS). 
Read more... 
http://www.worldpharmanews.com/content/view/957/1/
 
The Lilly TB Drug Discovery Initiative Announces New Collaborator 
On behalf of The Lilly TB Drug Discovery Initiative, the Infectious Disease Research Institute (IDRI) signed a Memorandum of Understanding (MOU) with Academia Sinica, a research institution based in Taiwan, to collaborate in target-based screening for the discovery of new tuberculosis (TB) drugs. The Lilly TB Drug Discovery Initiative's most important goal is filling the pipeline for faster, future TB drug development. 
Read more... 
http://www.worldpharmanews.com/content/view/956/1/
 
EU-funded researchers hunt down tumour killers using bacteria 
Infamous bacteria impacting our lives are Salmonellae, usually found in chicken and eggs. But are they getting too much of a bad rap? EU-funded researchers in Germany may have actually succeeded in putting a positive spin on Salmonellae following the discovery that the bacteria can migrate into solid tumours and destroy them. 
Read more... 
http://www.worldpharmanews.com/content/view/955/1/
 
New Capgemini study points to recovery in the life sciences industry 
A new report released by Capgemini, one of the world's foremost providers of consulting, technology and outsourcing services, highlights the significant challenges faced by the life sciences industry in the current global market. Capgemini's Vision and Reality Report 2009 provides an in-depth look at the current global market for the life sciences industries including pharmaceutical, medical device, biotech and agribusiness. 
Read more... 
http://www.worldpharmanews.com/content/view/954/1/
 
Abbott to Acquire Solvay Pharmaceuticals Business 
Abbott today announced a definitive agreement with the Solvay Group for Abbott to acquire Solvay's pharmaceuticals business for EUR 4.5 billion ($6.6 billion) in cash, providing Abbott with a large and complementary portfolio of pharmaceutical products and a significant presence in key global emerging markets. 
Read more... 
http://www.worldpharmanews.com/content/view/953/1/
 
Novartis bronchodilator QAB149 recommended for approval in European Union 
Novartis has received a positive opinion recommending European Union (EU) approval of QAB149 (indacaterol) for maintenance bronchodilator treatment in adult patients with chronic obstructive pulmonary disease (COPD). When approved, QAB149 and its device, Concept-1, will be known as Onbrez® Breezhaler®[§]. 
Read more... 
http://www.worldpharmanews.com/content/view/952/1/
 
Results from Abbott's PROSPECT Study Provide New Insight 
Abbott (NYSE: ABT) announced primary results from its ground breaking PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) clinical trial. PROSPECT is the first prospective natural history study to evaluate the role of vulnerable plaque in unexpected heart attacks and the natural progression of coronary artery disease. 
Read more... 
http://www.worldpharmanews.com/content/view/951/1/
 
PharmaNews.eu / Latest News
 
European Medicines Agency recommends authorisation of additional vaccine for influenza pandemic (H1N1) 2009
http://www.pharmanews.eu/emea/340-european-medicines-agency-recommends-authorisation-of-additional-vaccine-for-influenza-pandemic-h1n1-2009
 
 
Herceptin provides impressive survival benefit for patients with high levels of HER2 in their stomach cancer
http://www.pharmanews.eu/roche/338-herceptin-provides-impressive-survival-benefit-for-patients-with-high-levels-of-her2-in-their-stomach-cancer
 
 
 
 
 
 
European Medicines Agency recommends authorisation of two vaccines for influenza pandemic (H1N1) 2009
http://www.pharmanews.eu/emea/332-european-medicines-agency-recommends-authorisation-of-two-vaccines-for-influenza-pandemic-h1n1-2009
 
 
With best regards,
Ruslan David, MD
Administrator/Editor
 
 
PS:
Subscribe to World Pharma News alerts by Email (a free service delivered by Google) -
http://feedburner.google.com/fb/a/mailverify?uri=worldpharmanews&loc=en_US
 
Subscribe to PharmaNews.eu alerts by Email (a free service delivered by Google) -
http://feedburner.google.com/fb/a/mailverify?uri=pharmanewseu&loc=en_US
Reply all
Reply to author
Forward
0 new messages